Increased Radiotracer Uptake on Positron Emission Tomography After Invasive Thoracic Procedures: A Case Series

Festic, Emir; Abraham, Philip J.; Burnett, Omer L.; Young, Phillip M.; Johnson, Margaret M.
September 2007
Mayo Clinic Proceedings;Sep2007, Vol. 82 Issue 9, p1060
Academic Journal
OBJECTIVE: To investigate the hypothesis that tissue changes induced by invasive thoracic procedures may be associated with increased fluorine 18-labeled fluorodeoxyglucose (FDG) uptake on positron emission tomography (PET) scans, potentially leading to these tissue changes being mistaken for malignancies. PATIENTS AND METHODS: We retrospectively reviewed the records of all patients undergoing bronchoscopies and FDG-PET at Mayo Clinic Jacksonville from February 2002 to September 2004 and identified patients who had undergone computed tomography (CT) of the chest and bronchoscopy before FDG-PET. We identified and reviewed the imaging studies of patients who had increased FDG uptake on PET scans and whose CT scans showed no corresponding abnormalities suggestive of malignancy. RESULTS: Eighty-one patients had undergone both bronchoscopy and PET within the defined study period. Of these, 45 (56%) underwent PET within 4 weeks after bronchoscopy, and 13 (29%) of these 45 patients had increased FDG uptake on PET scans that did not correlate with pathological findings on CT. We Judged that increased uptake on 3 (23%) of the 13 PET scans was most likely related to the bronchoscopic procedure. Additionally, 2 patients who had undergone theracoscopy after bronchoscopy but before PET had discordant CT and PET findings. CONCLUSION: Invasive thoracic procedures may cause an increased uptake of radiotracer on PET scans that could be mistakenly interpreted as evidence of malignancy. To avoid clinical misjudgment, clinicians should perform PET before invasive thoracic procedures.


Related Articles

  • An In Vitro Assay for Predicting Successful Imaging Radiotracers. Patel, Shil; Hamill, Terence; Hostetler, Eric; Burns, H. Donald; Gibson, Raymond E. // Molecular Imaging & Biology;Mar2003, Vol. 5 Issue 2, p65 

    PURPOSE: To develop an in vitro binding assay able to predict whether a radiolabel is likely to be a useful clinical tracer for positron emission tomography (PET).PROCEDURES: Rodent and rhesus brain sections were incubated with radioligands, most of which are tritiated or iodinated versions of...

  • PET imaging with 11C-acetate in prostate cancer: a biochemical, radiochemical and clinical perspective. Soloviev, Dmitri; Fini, Alberto; Chierichetti, Franca; Al-Nahhas, Adil; Rubello, Domenico // European Journal of Nuclear Medicine & Molecular Imaging;May2008, Vol. 35 Issue 5, p942 

    In the present study, the potential clinical role of 11C-acetate PET mainly in the differential diagnosis, in the staging and in the follow-up of prostate cancer patients is reported. Each of the above points has been accurately investigated by studying the specific biochemical and...

  • The Simplified Reference Tissue Model with 18F-Fallypride Positron Emission Tomography: Choice of Reference Region. Ishibashi, Kenji; Robertson, Chelsea L.; Mandelkern, Mark A.; Morgan, Andrew T.; London, Edythe D. // Molecular Imaging;Nov/Dec2013, Vol. 12 Issue 8, p509 

    The development of high-affinity radiotracers for positron emission tomography (PET) has allowed for quantification of dopamine receptors in extrastriatal and striatal regions of the brain. As these new radiotracers have distinctly different kinetic properties than their predecessors, it is...

  • Quantitative Effects of Contrast Enhanced CT Attenuation Correction on PET SUV Measurements. Tira Bunyaviroch; Timothy Turkington; Terence Wong; John Wilson; James Colsher; R. Coleman // Molecular Imaging & Biology;Mar2008, Vol. 10 Issue 2, p107 

    Abstract Purpose  The presence of contrast materials on computed tomography (CT) images can cause problems in the attenuation correction of positron emission tomography (PET) images. These are because of errors converting the CT attenuation of contrast to 511-keV attenuation and...

  • My PET Marker. Netterwald, James // Drug Discovery & Development;Oct2007, Vol. 10 Issue 10, p24 

    The article discusses the functions of Positron Emission Tomography (PET). The imaging system is used to measure emissions from radioactively-labeled, metabolically-active chemicals that reach the brain following injection into the bloodstream. Specialized sensors in the PET scanner detect the...

  • Performance evaluation of the Philips MOSAIC small animal PET scanner. Huisman, Marc C.; Reder, Sybille; Weber, Axel W.; Ziegler, Sibylle I.; Schwaiger, Markus // European Journal of Nuclear Medicine & Molecular Imaging;Apr2007, Vol. 34 Issue 4, p532 

    In this study an evaluation of the performance of the Philips MOSAIC small animal PET scanner is presented, with special emphasis on the ability of the system to provide quantitatively accurate PET images. The performance evaluation was structured according to NEMA-like procedures. The...

  • VIRTUAL BRONCHOSCOPY: OUR EARLY EXPERIENCE. Bradoo, Renuka A.; Nerurkar, Nupur Kapoor; Joshi, Anagha Rajeev; Shah, Jayesh // Indian Journal of Otolaryngology & Head & Neck Surgery;Apr-Jun2005, Vol. 57 Issue 2, p142 

    Virtual bronchoscopy is one of the many new radiological scanning techniques that have been recently introduced. Virtual endoscopy, according to Ahlquist (Ahlquist and Johnson CD, Gastroenterology, 112, 1997, 2150) is a technique for visualizing interior cavities using computer graphic...

  • Assessment of cancer-associated biomarkers by positron emission tomography: Advances and challenges. Collier, T. Lee; Lecomte, Roger; McCarthy, Timothy J.; Meikle, Steve; Ruth, Thomas J.; Scopinaro, Francesco; Signore, Alberto; VanBrocklin, Henry; Van de Wiel&, Christophe; Waterhouse, Rikki N. // Disease Markers;2002, Vol. 18 Issue 5/6, p211 

    Positron emission tomography (PET) provides a powerful means to non-invasively image and quantify protein expression and biochemical changes in living subjects at nano- and picomolar levels. As the field of molecular imaging develops, and as advances in the biochemistry, pharmacology,...

  • Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Basu, Sandip; Kwee, Thomas; Gatenby, Robert; Saboury, Babak; Torigian, Drew; Alavi, Abass // European Journal of Nuclear Medicine & Molecular Imaging;Jun2011, Vol. 38 Issue 6, p987 

    The author reflects on the evolving role of molecular imaging with positron emission tomography (PET) in detecting and characterizing heterogeneity of cancer tissue. The author states that molecular imaging with PET has been regarded as a true classifier of tumor cell characteristics for it can...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics